Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed attachment file name title question first answered answering member label
tabling member	label

Search

170844

	registered interest
	date	16/12/2014
	answering body	Cabinet Office
	answering dept id	53
	answering dept short name	Cabinet Office
	answering dept sort name	Cabinet Office
	hansard heading	Peers
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government how many nominations for peerages by each political party have been blocked by the House of Lords Appointments Commission in each of the Parliaments since its formation in 2000.
	tabling member printed	Lord Avebury
	uin	HL3791
	answer	answer is ministerial correction date of answer 26/01/2015 answer text <p>The government does not hold information on nominations blocked by the House of Lords Appointments Commission. This is a matter for the House of Lords Appointment Commission who are an independent, advisory, non-departmental public body.</p><p> </p> answering member printed Lord Wallace of Saltaire question first answered 26/01/2015 17:39:49 answering member 1816 label Biography information for Lord Wallace of Saltaire
	tabling member	1665 label Biography information for Lord Avebury

44163

	registered interest
	date	19/03/2014
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many applications have been received by United Kingdom entry clearance posts for adult dependant settlement visas from 31 July 2012, to the latest convenient date; and how many such visas were granted over the same period.
	tabling member printed	Lord Avebury
	uin	HL6119
	answer	answer is ministerial correction date of answer 26/03/2014 answer text <p> </p><p> </p><p> </p><p>The information requested on entry clearance applications for adult dependent <br />relative settlement visas is not available and could only be obtained at <br />disproportionate cost by the examination of a significant number of individual <br />case records. <br /><br />The Home Office publishes quarterly statistics on entry clearance visa <br />applications and resolutions (issued, refused, withdrawn and lapsed) by <br />category in table be_01_q (Before Entry tables volume 2) within the <br />‘Immigration Statistics' release. A copy of the latest release, ‘Immigration <br />Statistics September – December 2013' is available from the Library of the <br />House and from: <br />https://www.gov.uk/government/organisations/home-office/series/immigration-stati<br />stics-quarterly-release.<br /><br />Within the table be_01_q , data relating to adult dependent relatives of a <br />British Citizen in the UK or a settled person in the UK are included in the <br />category ‘Family: Other (for immediate settlement)' but cannot be identified <br />separately.<br /><br />The Home Office is reviewing the collection of data relating to adult dependent <br />relative settlement visas. Data are being developed and, subject to resolving <br />any data quality/recording issues, it is planned to begin publishing data <br />specifically relating to adult dependent relative settlement visas later this <br />year.<br /><br />A manual review of the available management information to identify adult <br />dependent relative applications granted in the period from 1 November 2012 to <br />30 September 2013 indicates that 34 settlement visas were issued in that period <br />to an adult dependent relative under Appendix FM to the Immigration Rules. This <br />information is provisional and subject to change. Corresponding information on <br />applications is not available.</p><p> </p><p> </p><p> </p> answering member printed Lord Taylor of Holbeach question first answered 26/03/2014 12:00:00 answering member 3787 label Biography information for Lord Taylor of Holbeach
	tabling member	1665 label Biography information for Lord Avebury

79538

	registered interest
	date	23/07/2014
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Heathrow Airport
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what operations are conducted by the Port Medical Inspector in the space adjacent to the detention facilities in Heathrow Terminal 4; what plans Heathrow Airports Limited has for relocating that work elsewhere, including the timing of the move; and why Heathrow Airports Limited has not yet appointed a project manager for the work to upgrade the detention facilities at Heathrow, originally scheduled to start at the beginning of May.
	tabling member printed	Lord Avebury
	uin	HL1436
	answer	answer is ministerial correction date of answer 30/07/2014 answer text <p /> <p>The Port Medical Inspector is no longer using the space adjacent to the detention facilities at Heathrow Terminal 4. A Port Medical Inspector is available at Terminal 3 to undertake any necessary on entry referral screening.Heathrow Airport Ltd (HAL) is waiting for formal notice from the Port Medical Inspector that they wish to terminate their lease on the space. There is a 3 month notice period. In the meantime, free access to the area has been given to plan accommodation changes. HAL has now appointed a project manager.There is a meeting scheduled for 31 July between the Home Office and HAL to discuss the project timetable.</p><p /> answering member printed Lord Taylor of Holbeach question first answered 30/07/2014 15:31:22 answering member 3787 label Biography information for Lord Taylor of Holbeach
	tabling member	1665 label Biography information for Lord Avebury

170930

	registered interest
	date	17/12/2014
	answering body	The Lord Chairman of Committees
	answering dept id	200
	answering dept short name
	answering dept sort name	Chairman of Committees (HoL)
	hansard heading	House of Lords: Catering
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask the Chairman of Committees what has been (1) the expenditure, and (2) the profit or deficit, for the years 2012–13 and 2013–14 of each catering outlet in the House of Lords.
	tabling member printed	Lord Avebury
	uin	HL3837
	answer	answer is ministerial correction date of answer 06/01/2015 answer text <p>The turnover, expenditure and profit or loss of each Catering and Retail Service outlet in 2012-13 and 2013-14 are set out in the tables below.</p><p> </p><p><strong>2012-13</strong></p><p> </p><table><tbody><tr><td><p><strong>Outlet</strong></p></td><td><p><strong>Turnover (£)</strong></p></td><td><p><strong>Expenditure (£)</strong></p></td><td><p><strong>Profit/loss (£)</strong></p></td></tr><tr><td><p>Peers' Dining Room</p></td><td><p>491,364</p></td><td><p>1,308,224</p></td><td><p>-816,860</p></td></tr><tr><td><p>Barry Room</p></td><td><p>238,267</p></td><td><p>498,307</p></td><td><p>-260,040</p></td></tr><tr><td><p>Home Room</p></td><td><p>44,838</p></td><td><p>182,122</p></td><td><p>-137,284</p></td></tr><tr><td><p>River Restaurant</p></td><td><p>257,041</p></td><td><p>689,116</p></td><td><p>-432,075</p></td></tr><tr><td><p>Bishops Bar</p></td><td><p>51,399</p></td><td><p>111,197</p></td><td><p>-59,798</p></td></tr><tr><td><p>Peers Guest Room</p></td><td><p>59,952</p></td><td><p>56,524</p></td><td><p>3,428</p></td></tr><tr><td><p>Lords Bar</p></td><td><p>99,612</p></td><td><p>130,914</p></td><td><p>-31,302</p></td></tr><tr><td><p>Millbank House</p></td><td><p>90,139</p></td><td><p>205,036</p></td><td><p>-114,897</p></td></tr></tbody></table><p> </p><p><strong>2013-14</strong></p><table><tbody><tr><td><p><strong>Outlet</strong></p></td><td><p><strong>Turnover (£)</strong></p></td><td><p><strong>Expenditure (£)</strong></p></td><td><p><strong>Profit/loss (£)</strong></p></td></tr><tr><td><p>Peers' Dining Room</p></td><td><p>554,236</p></td><td><p>1,441,232</p></td><td><p>-886,996</p></td></tr><tr><td><p>Barry Room</p></td><td><p>204,882</p></td><td><p>466,362</p></td><td><p>-261,480</p></td></tr><tr><td><p>Home Room</p></td><td><p>29,503</p></td><td><p>163,502</p></td><td><p>-133,999</p></td></tr><tr><td><p>River Restaurant</p></td><td><p>258,457</p></td><td><p>703,978</p></td><td><p>-445,521</p></td></tr><tr><td><p>Bishops Bar</p></td><td><p>60,090</p></td><td><p>125,399</p></td><td><p>-65,310</p></td></tr><tr><td><p>Peers Guest Room</p></td><td><p>60,045</p></td><td><p>75,335</p></td><td><p>-15,290</p></td></tr><tr><td><p>Lords Bar</p></td><td><p>106,561</p></td><td><p>102,746</p></td><td><p>3,815</p></td></tr><tr><td><p>Millbank House</p></td><td><p>91,430</p></td><td><p>240,236</p></td><td><p>-148,806</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member printed Lord Sewel question first answered 06/01/2015 14:28:32 answering member 2124 label Biography information for Lord Sewel
	tabling member	1665 label Biography information for Lord Avebury

416951

	registered interest
	date	07/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services: Travellers
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is their assessment of each of the recommendations to the Department of Health in the report <i>Bridging the Gap between Academics and Policy Makers</i> by researchers from Buckinghamshire New University and the University of Bristol, published on 20 April.
	tabling member printed	Lord Avebury
	uin	HL1871
	answer	answer is ministerial correction date of answer 17/09/2015 answer text <p>We have made no assessment.</p><p> </p><p> </p><p> </p><p>NHS England, and all National Health Service organisations, have a duty to have due regard to the need to reduce health inequalities in access to health services and health outcomes achieved, as well as having regard to the different needs of groups with characteristics protected under the Equality Act 2010.</p><p> </p><p> </p><p> </p><p>As part of its contractual arrangements for provision of healthcare in prisons, NHS England expects that care planning and delivery of services must be equitable for all prisoners and take into consideration the diversity of the prison population. This would include Gypsies, Travellers and the Roma communities.</p><p> </p><p> </p><p> </p><p>The Equality Delivery System (EDS) for the NHS helps all NHS organisations, in discussion with local partners and patients, to review and improve their performance for people with characteristics protected under the Equality Act. By using the EDS, NHS organisations can ensure they are delivering on the public sector Equality Duty.</p><p> </p><p> </p><p> </p><p>Every person entering a place of detention will have an initial health screen at reception where health needs are assessed and where appropriate referrals are made to other services, including substance misuse services.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 17/09/2015 11:20:17 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	1665 label Biography information for Lord Avebury

425824

	registered interest
	date	03/11/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Stem Cells
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what progress has been made in implementing the recommendations of the 2014 report of the UK Stem Cell Strategy Oversight Committee on the future of unrelated donor stem cell transplantation in the United Kingdom.
	tabling member printed	Lord Avebury
	uin	HL3222
	answer	answer is ministerial correction date of answer 12/11/2015 answer text <p>The Government continues to take forward work to deliver the recommendations in the 2014 report. We remain committed to improving stem cell transplantation services and doing all we can to help those in need of a transplant to find a suitable donor.</p><br /><p>Since 2011, the Department has provided its delivery partners, NHS Blood and Transplant and the Anthony Nolan, a total of £16 million in additional, new funding to improve stem cell transplantation services in the United Kingdom. A further £3 million investment was announced in March 2015.</p><br /><p>This funding has led to a tangible improvement in the availability of stem cells in the UK and the achievements include:</p><br /><p>- More UK patients received a stem cell transplant in 2014 than ever before;</p><br /><p>- Over 60% of black, Asian and minority ethnic (BAME) patients are now able to find a well matched donor compared to only 40% in 2010;</p><br /><p>- A single unified bone marrow donor registry has been created streamlining the provision of stem cells and reducing the time to provide cells from adult donors;</p><br /><p>- The proportion of patients receiving cord blood from UK donors has significantly increased; and</p><br /><p>- An increase in UK patients receiving a transplant from 802 in 2010/11 to 1,060 in 1013/14. The increased use of UK-sourced stem cells has meant that more donors than ever are available to donate leading to a significant cost saving by reducing the need to import stem cells.</p><br /> <br /> answering member printed Lord Prior of Brampton question first answered 12/11/2015 13:06:57 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	1665 label Biography information for Lord Avebury

426401

	registered interest
	date	05/11/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government which drugs have been delisted from the Cancer Drugs Fund; how many patients are currently being treated with each drug; and what steps they are taking to develop a new system for prescribing each drug.
	tabling member printed	Lord Avebury
	uin	HL3340
	answer	answer is ministerial correction date of answer 19/11/2015 answer text <p>Details of the drugs removed from the national Cancer Drugs Fund (CDF) list following re-prioritisation are shown in tables 1 and 2. The latest version of the list is available on NHS England’s website at: <a href="http://www.england.nhs.uk/ourwork/pe/cdf/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/</a>. A copy is attached.</p><br /><table><tbody><tr><td colspan="2"><p>Table 1: Confirmation of previously notified drugs and indications delisted on 12 March 2015</p></td></tr><tr><td><p>Drug</p></td><td><p>Indication removed</p></td></tr><tr><td><p>Aflibercept</p></td><td><p>2nd line in combination with irinotecan-based combination chemotherapy for metastatic colorectal cancer</p></td></tr><tr><td><p>Bendamustine</p></td><td><p>Treatment of patients with indolent non-Hodgkin’s lymphoma who are refractory to rituximab</p></td></tr><tr><td><p>Bevacizumab</p></td><td><p>1st line in combination with oxaliplatin–based combination chemotherapy for metastatic colorectal cancer</p></td></tr><tr><td><p>Bevacizumab</p></td><td><p>1st line in combination with irinotecan–based combination chemotherapy for metastatic colorectal cancer</p></td></tr><tr><td><p>Bevacizumab</p></td><td><p>1st line in combination with single agent fluoropyrimidine–based chemotherapy for metastatic colorectal cancer.</p></td></tr><tr><td><p>Bevacizumab</p></td><td><p>In combination with carboplatin and gemcitabine chemotherapy for recurrent platinum sensitive ovarian cancer</p></td></tr><tr><td><p>Bortezomib</p></td><td><p>Re-treatment in patients with relapsed myeloma</p></td></tr><tr><td><p>Bortezomib</p></td><td><p>Treatment of patients with relapsed Waldenstrom’s macroglobulinaemia</p></td></tr><tr><td><p>Bortezomib</p></td><td><p>Treatment of patients with relapsed mantle cell lymphoma</p></td></tr><tr><td><p>Bosutinib</p></td><td><p>Treatment of blast phase chronic myeloid leukaemia</p></td></tr><tr><td><p>Cetuximab</p></td><td><p>2nd line in combination with irinotecan chemotherapy for metastatic colorectal cancer in patients with RAS wild type (non-mutated) tumours</p></td></tr><tr><td><p>Dasatinib</p></td><td><p>Treatment of the lymphoid blast phase of chronic myeloid leukaemia</p></td></tr><tr><td><p>Everolimus</p></td><td><p>Treatment of progressive unresectable or metastatic well differentiated neuroendocrine tumour of the pancreas</p></td></tr><tr><td><p>Lapatinib</p></td><td><p>In combination with capecitabine chemotherapy for HER-2 receptor positive locally advanced or metastatic breast cancer</p></td></tr><tr><td><p>Ofatumumab</p></td><td><p>Treatment of relapsed or refractory chronic lymphatic leukaemia</p></td></tr><tr><td><p>Pazopanib</p></td><td><p>Treatment of previously treated metastatic non-adipocytic soft tissue sarcomas</p></td></tr><tr><td><p>Pegylated liposomal doxorubicin</p></td><td><p>1st or 2nd line chemotherapy of angiosarcoma</p></td></tr><tr><td><p>Pegylated liposomal doxorubicin</p></td><td><p>Chemotherapy of primary malignant sarcomas of the heart and great vessels</p></td></tr><tr><td colspan="2"><p>Source: National Cancer Drugs Fund List Ver 6.0</p></td></tr></tbody></table><br /><table><tbody><tr><td colspan="2"><p>Table 2: Confirmation of previously notified drugs and indications delisted on 4 November 2015</p></td></tr><tr><td><p>Drug</p></td><td><p>Indication removed</p></td></tr><tr><td><p>Albumin bound Paclitaxel</p></td><td><p>First line treatment of advanced adenocarcinoma of the pancreas in combination with Gemcitabine</p></td></tr><tr><td><p>Bendamustine</p></td><td><p>2<sup>nd </sup>or subsequent line treatment of chronic lymphatic leukaemia for patients whom fludarabine combination therapy is not a therapeutic option</p></td></tr><tr><td><p>Bendamustine</p></td><td><p>2<sup>nd </sup>and subsequent line of treatment of mantle cell lymphoma in patients who have not received previous Bendamustine</p></td></tr><tr><td><p>Bevacizumab</p></td><td><p>Treatment of patients with triple negative metastatic breast cancer and/or prior Taxane therapy</p></td></tr><tr><td><p>Bevacizumab</p></td><td><p>2<sup>nd </sup>or 3<sup>rd </sup>line treatment of metastatic colorectal cancer in combination with standard chemotherapy in patients who have not previously received Bevacizumab</p></td></tr><tr><td><p>Bosutinib</p></td><td><p>Treatment of chronic phase CML refractory to Nilotinib or Dasatinib</p></td></tr><tr><td><p>Bosutinib</p></td><td><p>Treatment of accelerated phase CML refractory to Nilotinib or Dasatinib</p></td></tr><tr><td><p>Bosutinib</p></td><td><p>Treatment of accelerated phase CML where there is significant intolerance to Dasatinib and Nilotinib.</p></td></tr><tr><td><p>Cetuximab</p></td><td><p>3<sup>rd </sup>and subsequent line treatment of metastatic colorectal cancer as a single agent</p></td></tr><tr><td><p>Cetuximab</p></td><td><p>3rd and subsequent line treatment of metastatic colorectal cancer as a single agent in patients not treated to progression under NICE TA176</p></td></tr><tr><td><p>Dasatinib</p></td><td><p>Treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy including Imatinib</p></td></tr><tr><td><p>Everolimus</p></td><td><p>2<sup>nd </sup>or 3<sup>rd </sup>line treatment of metastatic renal cell carcinoma where disease has progressed on or after treatment with VEGF-targeted therapy</p></td></tr><tr><td><p>Lenalidomide</p></td><td><p>2<sup>nd </sup>line treatment of multiple myeloma in patients who have contraindications to the use of Bortezomib</p></td></tr><tr><td><p>Panitumumab</p></td><td><p>3rd and subsequent line treatment of metastatic colorectal cancer as a single agent</p></td></tr><tr><td><p>Panitumumab</p></td><td><p>3rd and subsequent line treatment of metastatic colorectal cancer as a single agent in patients not treated to progression under NICE TA176</p></td></tr><tr><td><p>Pegylated Liposomal Doxorubicin</p></td><td><p>2nd line treatment of Fibromatosis</p></td></tr><tr><td><p>Peptide Receptor Radionucleotide Therapy (Lutetium177 Octreotate or Yttrium90 Octreotide/Octreotate)</p></td><td><p>Treatment of advanced neuro-endocrine tumours i.e. for pNETS after Sunitinib/chemotherapy, for mid-gut carcinoid, after octreotide/somatostatin therapies.</p></td></tr><tr><td><p>Pomalidomide</p></td><td><p>Treatment of relapsed and refractory multiple myeloma in patients who have received at least 2 prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy</p></td></tr><tr><td colspan="2"><p>Source: National Cancer Drugs Fund List Ver 6.0</p></td></tr></tbody></table><br /><p>NHS England publishes information on the number of patient applications for particular drugs/indications contained on the national CDF list on a quarterly basis. This information also includes the number of applications approved through the individual CDF request process. The latest information isattached as it is too long to be included in this answer. It is also available at:</p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/</a> and a copy of this is also attached.</p><br /><p>The Government is committed to the CDF and is working with NHS England and the National Institute for Health and Care Excellence on the future arrangements for the Fund.</p> answering member printed Lord Prior of Brampton attachment 1 file name ID3780736_HL3340 Library Depost CDF List.pdf title Cancer Drugs Fund List 2 file name CDF reporting template (1).xlsx title CDF Reporting template 3 file name HL3340 Library Depost patient numbers.docx title Patient Numbers question first answered 19/11/2015 14:54:51 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	1665 label Biography information for Lord Avebury

77763

	registered interest
	date	14/07/2014
	answering body	Foreign and Commonwealth Office
	answering dept id	16
	answering dept short name	Foreign and Commonwealth Office
	answering dept sort name	Foreign and Commonwealth Office
	hansard heading	Internet
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what if any financial arrangements they have with the Internet Computer Bureau which allow the latter to make money from the sale of dependent territory domain names.
	tabling member printed	Lord Avebury
	uin	HL1060
	answer	answer is ministerial correction date of answer 11/08/2014 answer text <p>The British Government has no financial arrangement with the Internet Computer Bureau, which is the Domain Name Registrar or Network Information Centre for a number of domains including for some of the Overseas Territories.</p> answering member printed Lord Popat question first answered 11/08/2014 11:30:21 answering member 4173 label Biography information for Lord Popat
	tabling member	1665 label Biography information for Lord Avebury

79732

	registered interest
	date	29/07/2014
	answering body	Foreign and Commonwealth Office
	answering dept id	16
	answering dept short name	Foreign and Commonwealth Office
	answering dept sort name	Foreign and Commonwealth Office
	hansard heading	Malaysia
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, further to the Written Answer by Baroness Warsi on 21 January (WA 136), what progress has been made in resuming the European Union–Malaysia Human Rights Dialogue; and whether they have asked the government of Malaysia how it reconciles the endorsement of the 2004 Amman Message (recognising the validity of all eight Islamic legal schools including Shia) with actions taken by the Malaysian authorities.
	tabling member printed	Lord Avebury
	uin	HL1624
	answer	answer is ministerial correction date of answer 11/08/2014 answer text <p>Discussions continue between the EU and Malaysia on the resumption of the EU-Malaysia Human Rights Dialogue. We are keen to have a Dialogue of substance. Bilaterally, we have regular conversations with the Malaysian government on human rights issues, including freedom of religion.</p><p> </p> answering member printed Lord Popat question first answered 11/08/2014 11:22:10 answering member 4173 label Biography information for Lord Popat
	tabling member	1665 label Biography information for Lord Avebury

347899

	registered interest
	date	02/06/2015
	answering body	HM Treasury
	answering dept id	14
	answering dept short name	Treasury
	answering dept sort name	Treasury
	hansard heading	Social Security Benefits
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the report by the Organisation for Economic Co-operation and Development <i>In It Together: Why Less Inequality Benefits All</i>; and whether they plan to reconsider further cuts in benefits in the light of that assessment.
	tabling member printed	Lord Avebury
	uin	HL185
	answer	answer is ministerial correction date of answer 15/06/2015 answer text <p>The Government considers reports and publications from external organisations on an ongoing basis as part of the policy making process. The UK has one of the most redistributive tax and welfare systems in Europe, supported by a labour market that is continuing to perform strongly. UK income inequality is lower than in 2010 and the gender pay gap is at its lowest since records began. The government is committed to its path of fiscal consolidation, so will continue to making savings in public expenditure, including in welfare. The Chancellor will set out further detail on the composition of spending and welfare changes at the forthcoming Budget and Spending Review.</p><p> </p> answering member printed Lord O'Neill of Gatley question first answered 15/06/2015 12:10:23 answering member 4536 label Biography information for Lord O'Neill of Gatley
	tabling member	1665 label Biography information for Lord Avebury